Page 62 - ITPS-8-3

INNOSC Theranostics and
Pharmacological Sciences Precision medicine and beyond in oncology

colorectal cancer: Pioneering new avenues in solid tumor hereditary breast cancer: American society of clinical
immunotherapy. J Clin Oncol. 2025;43(8):994-1005. oncology, American Society for radiation oncology,
doi: 10.1200/jco-24-02081 and society of surgical oncology guideline. J Clin Oncol.
2020;38(18):2080-2106.
101. Zhu Y, Zuo D, Wang K, et al. Mesothelin-targeted CAR-T
therapy combined with irinotecan for the treatment of solid doi: 10.1200/jco.20.00299
cancer. J Cancer Res Clin Oncol. 2023;149(16):15027-15038. 112. Wang J, Zhang Y, Yuan L, Ren L, Zhang Y, Qi X.
doi: 10.1007/s00432-023-05279-9 Comparative efficacy, safety, and acceptability of single-
agent poly (ADP-ribose) polymerase (PARP) inhibitors
102. Buscail L, Bournet B, Cordelier P. Role of oncogenic KRAS in BRCA-mutated HER2-negative metastatic or advanced
in the diagnosis, prognosis and treatment of pancreatic breast cancer: A network meta-analysis. Aging (Albany NY).
cancer. Nat Rev Gastroenterol Hepatol. 2020;17(3):153-168. 2020;13(1):450-459.
doi: 10.1038/s41575-019-0245-4 doi: 10.18632/aging.202152
103. Tew BY, Durand JK, Bryant KL, et al. Genome-wide 113. Lu X, Deng S, Xu J, et al. Combination of AFP vaccine
DNA methylation analysis of KRAS mutant cell lines. Sci and immune checkpoint inhibitors slows hepatocellular
Rep. 2020;10(1):10149. carcinoma progression in preclinical models. J Clin Invest.
doi: 10.1038/s41598-020-66797-x 2023;133(11):e163291.
104. Strickler JH, Satake H, George TJ, et al. Sotorasib in KRAS doi: 10.1172/jci163291
p.G12C-mutated advanced pancreatic cancer. N Engl J Med. 114. Zhong L, Gan L, Wang B, et al. Hyperacute rejection-
2023;388(1):33-43.
engineered oncolytic virus for interventional clinical trial in
doi: 10.1056/NEJMoa2208470 refractory cancer patients. Cell. 2025;188(4):1119-1136.e23.
105. Cilliers C, Howgate E, Jones HM, Rahbaek L, Tran JQ. doi: 10.1016/j.cell.2024.12.010
Clinical and physiologically based pharmacokinetic model
evaluations of adagrasib drug-drug interactions. Clin 115. Aggeletopoulou I, Pantzios S, Triantos C. Personalized
immunity: Neoantigen-based vaccines revolutionizing
Pharmacol Ther. 2025;117(3):732-741.
hepatocellular carcinoma treatment. Cancers (Basel).
doi: 10.1002/cpt.3506 2025;17(3):376.
106. Peng TR, Wu TW, Yi TY, Wu AJ. Comparative efficacy of doi: 10.3390/cancers17030376
adagrasib and sotorasib in KRAS G12C-mutant NSCLC:
Insights from pivotal trials. Cancers. 2024;16(21):3676. 116. Xu Z, Ji G, Cui Y, Cui X. The impacts of non-coding RNAs
and N(6)-methyladenosine on cancer: Past, present and
107. Kaufman B, Shapira-Frommer R, Schmutzler RK, et future. Curr Cancer Drug Targets. 2021;21(5):375-385.
al. Olaparib monotherapy in patients with advanced
cancer and a germline BRCA1/2 mutation. J Clin Oncol. doi: 10.2174/1568009621999210120193636
2015;33(3):244-250. 117. Liu W, Gao X, Chen X, et al. miR-139-5p loss-mediated
doi: 10.1200/jco.2014.56.2728 WTAP activation contributes to hepatocellular carcinoma
progression by promoting the epithelial to mesenchymal
108. Javle M, Shacham-Shmueli E, Xiao L, et al. Olaparib transition. Front Oncol. 2021;11:611544.
monotherapy for previously treated pancreatic cancer with
DNA damage repair genetic alterations other than germline doi: 10.3389/fonc.2021.611544
BRCA variants: Findings from 2 phase 2 nonrandomized 118. Ma JZ, Yang F, Zhou CC, et al. METTL14 suppresses
clinical trials. JAMA Oncol. 2021;7(5):693-699. the metastatic potential of hepatocellular carcinoma by
doi: 10.1001/jamaoncol.2021.0006 modulating N6‐methyladenosine‐dependent primary
MicroRNA processing. Hepatology. 2017;65(2):529-543.
109. Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with
advanced breast cancer and a germline BRCA mutation. doi: 10.1002/hep.28885
N Engl J Med. 2018;379(8):753-763. 119. Wei J, Fang DL, Zhou W, He YF. N6-methyladenosine (m6A)
doi: 10.1056/NEJMoa1802905 regulatory gene divides hepatocellular carcinoma into three
subtypes. J Gastrointest Oncol. 2021;12(4):1860-1872.
110. Bruin MAC, Sonke GS, Beijnen JH, Huitema ADR.
Pharmacokinetics and pharmacodynamics of doi: 10.21037/jgo-21-378
PARP inhibitors in oncology. Clin Pharmacokinet. 120. Yankova E, Blackaby W, Albertella M, et al. Small-molecule
2022;61(12):1649-1675. inhibition of METTL3 as a strategy against myeloid
doi: 10.1007/s40262-022-01167-6 leukaemia. Nature. 2021;593(7860):597-601.
111. Tung NM, Boughey JC, Pierce LJ, et al. Management of doi: 10.1038/s41586-021-03536-w

Volume 8 Issue 3 (2025) 56 doi: 10.36922/ITPS025140018